We adopted multiplex immunofluorescence labelling of CD4+ T cells, Tregs (T regulatory cells CD4+, Foxp3+), CD8+ T cells, and B cells (B220+), at 12 weeks and ethical endpoints in the mouse APs tumours (Fig. 4a, b, respectively). This evidence concerns the gene CD4 and neoplasm.